Bavarian Nordic A/S
(OTC: BVNRY)
|
3:43 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $8.43 | Change: +0.15 | %Change: +1.86% | Volume: 860 |
Open: | $ 8.41 | Volume: | 860 | |
---|---|---|---|---|
High: | $ 8.43 | Yield(%) | 0.00 | |
Low: | $ 8.41 | P/E Ratio (ttm): | 13.44 | |
Dividend ($): | 0.54 | Market Cap ($): | 1.94B | |
EPS ($) | 0.62 | Shares Out: | 233.80M |
% Price Change (last 4 weeks): | -6.09 |
---|---|
% Price Change (last 13 weeks): | 6.11 |
% Price Change (last 26 weeks): | -6.93 |
% Price Change (last 52 weeks): | -10.28 |
% Price Change (year to date): | -5.31 |
Return on Equity (%): | 16.73 |
---|---|
Return on Assets (%): | 10.96 |
Return on Invested Capital (%): | -0.47 |
Gross Profit Margin (%): | 64.07 |
---|---|
Net Profit Margin (%): | 20.90 |
Operating Profit Margin (%): | 21.22 |
|
|
50-day Moving Average: | $7.58 |
---|---|
200-day Moving Average: | $7.37 |
Avg. Daily Vol. (last 50 days): | 3,796 |
Avg. Daily Vol. (last 200 days): | 5,082 |
52-wk high: | $9.62 |
52-wk low: | $5.95 |
Bid: | $n/a |
Ask: | $n/a |
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
|
Bavarian Nordic A/S
Philip Heymans Alle 3 Hellerup CR 2900 Phone: 45.33.26.83.83 Fax: n/a http://www.bavarian-nordic.com |
Earnings (1year) ($): | 0.62 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | 13.44 |
Book Value ($): | 6.54 |
Cash Flow ($): | 1.26 |
Price/Earnings (x): | 13.44 |
---|---|
Price/Sales (x): | 1.97 |
Price/Book (x): | 1.34 |
Price/Cash Flow (x): | 12.42 |
Quick Ratio (x): | 1.35 |
---|---|
Current Ratio (x): | 1.94 |
LT Debt/Equity (x): | 0.96 |
Total Debt/Equity (x): | 1.41 |